Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

mRNA vaccination in octogenarians 15 and 20 months after recovery from COVID-19 elicits robust immune and antibody responses that include Omicron

Cell Reports(2022)10.1016/j.celrep.2022.110680Source: DataRank Database

mRNA vaccination in octogenarians 15 and 20 months after recovery from COVID-19 elicits robust immune and antibody responses that include Omicron is a research paper published in Cell Reports (2022). On theSindex it has a DataRank of 0. It has been cited 43 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access43 citations

Download PDF

Cite:

Linked data & code

geo gen

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (4 grants)Impact (FWCI 4.25)OA: goldTopics (44)IDs (PubMed, PMC, OpenAlex)Annotations (2)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (11)

Ludwig Knabl ORCID,Juan I. Moliva ORCID,Anne P. Werner ORCID,Seyhan Boyoglu-Barnum,Sebastian Kapferer

Live enrichment

PubMed:35395191 PMC:PMC8947943 OpenAlex:https://openalex.org/W4221019311

National Institute of Allergy and Infectious Diseases

National Institute of Diabetes and Digestive and Kidney Diseases

National Institutes of Health

Vaccine Research Center

FWCI

4.25

Citation Percentile

1.0%

Citation Trend

2022

2023

2024

2025

2026

goldLicense: http://creativecommons.org/licenses/by-nc-nd/4.0/

journalhttp://www.cell.com/article/S2211124722004326/pdf

publisherhttp://www.cell.com/article/S2211124722004326/pdf

publisherhttps://api.elsevier.com/content/article/PII:S2211124722004326?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2211124722004326?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.celrep.2022.110680

Fields of Study

SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesImmunotherapy and Immune Responses

MeSH Terms

COVID-19SARS-CoV-2mRNA VaccinesOctogenariansBNT162 VaccineAgedAged, 80 and overAntibodies, ViralAntibody FormationHumansImmunoglobulin GRNA, MessengerVaccinationVaccines, SyntheticAntibodies, NeutralizingSpike Glycoprotein, Coronavirus

Keywords

AntibodyVaccinationImmunologyImmune systemPopulationNeutralizing antibodyBiologyVirologyMedicineCoronavirusDiseaseCoronavirus disease 2019 (COVID-19)Infectious disease (medical specialty)Internal medicineCytokinePBMCNeutralizationOctogenarianSars-cov-2Bnt162b2 VaccineOmicronCp: MicrobiologyNaive Versus Covid-19-recovered IndividualsImmune TranscriptomeIghv Clones

Sustainable Development Goals

SDG 0: Good health and well-being

mRNA vaccination in octogenarians 15 and 20 months after recovery from COVID-19 elicits robust immune and antibody responses that include Omicron

FAIR Checklist

Authors (11)

Funding (4 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)